Internal Medicine, Infectious Disease · Mansfield, TX
NPI
1164677613
Since 2008
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
350 Matlock Rd Ste 201
Mansfield, TX, 76063
Phone (817) 539-9091
Groups this clinician bills Medicare through
Medicare paid, 2024
$145K
11,440 services
Medicare patients, 2024
388
Average age 74
Drug cost, 2024
$263K
1,237 prescriptions
Company payments, 2025
$185
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Devak G Desai was code 99232 (hospital e&m - subsequent), 893 times for 278 patients. In total Devak G Desai billed 11,440 services in 23 codes, and Medicare paid $145K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 893 | 278 | $58.65 | $52K |
| 99222 Hospital E&M - Initial | Facility | 96 | 93 | $95.93 | $9,209 |
| 99214 Office E&M - Established | Office | 73 | 51 | $93.08 | $6,795 |
| 99215 Office E&M - Established | Office | 61 | 42 | $134.06 | $8,178 |
| 99223 Hospital E&M - Initial | Facility | 61 | 61 | $126.09 | $7,691 |
| 99291 Critical Care E&M | Facility | 20 | 19 | $160.08 | $3,202 |
By year: 2022 $154K for 31,249 services; 2023 $145K for 8,552 services; 2024 $145K for 11,440 services.
Medicare prescription drug claims, 2024
In 2024, the drug Devak G Desai prescribed most often to Medicare patients was Ceftriaxone (Ceftriaxone Sodium), with 149 prescriptions and refills. In total Devak G Desai wrote 1,237 Medicare prescriptions that cost $263K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ceftriaxone Ceftriaxone Sodium | 149 | 149 | 35 | $12K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 149 | 171 | 38 | $2,033 |
| Vancomycin Hcl Generic | 119 | 119 | 30 | $17K |
| Cephalexin Generic | 109 | 115 | 33 | $2,463 |
| Daptomycin Generic | 108 | 108 | 24 | $49K |
| Ertapenem Ertapenem Sodium | 102 | 102 | 30 | $38K |
| Cefepime Hcl Generic | 68 | 68 | 17 | $9,832 |
| Doxycycline Hyclate Generic | 65 | 83 | 22 | $2,404 |
| Amoxicillin Generic | 34 | 41 | 11 | $391 |
| Meropenem Generic | 33 | 33 | Under 11 | $9,975 |
| Fluconazole Generic | 32 | 36 | Under 11 | $414 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 28 | 35 | 13 | $869 |
| Ciprofloxacin Hcl Generic | 22 | 22 | 12 | $381 |
| Vancomycin Hcl Vancomycin/Water For Inj (Peg) | 19 | 19 | Under 11 | $3,863 |
| Epinephrine Generic | 17 | 17 | 17 | $4,402 |
Brand drugs: 110 claims; generic drugs: 1,127 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Devak G Desai $185 ($185 in general payments such as food, travel and fees) from 3 companies. The largest payer was Gilead Sciences, Inc. with $135.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.